InsidersTradesSigma
Beyond Air, Inc. Stock: price and management transactions · United States · SEC (Form 4)
Follow the Beyond Air, Inc. share price and the full management transaction log of the company, a listed issuer based in United States. Shares are quoted on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Beyond Air, Inc. has published 70 reports. Market capitalisation: €4.4m. The latest transaction was reported on 31 July 2026 (Acquisition). Among the most active insiders: Carey Robert. All data is free.
70
Insider Decl.
n/a
Thresholds
€10m
49 ops.
Buy Volume
€2m
8 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Beyond Air, Inc. Buy (bullish), based on 2 analysts. Average price target: US$160.00.
60Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 31 July 2026
Declarations70 total
4,340 shares@ US$5.76Common StockSEC:0001493152-26-035700:0
Canonical exit: 27 Oct 2026 (T+90)
34,722 shares@ US$5.76Common StockSEC:0001493152-26-035702:0
Canonical exit: 27 Oct 2026 (T+90)
6,000 shares@ US$3.24850.5% of flowCommon StockSEC:0001641172-25-020696:0
Canonical exit: 19 Oct 2025 (T+90)
990,000 shares@ US$0.252.2% of flowCommon StockSEC:0001493152-25-010501:0
Canonical exit: 12 Jun 2025 (T+90)
6,000 shares@ US$0.38232.0% of flowCommon StockSEC:0001493152-25-007901:0
Canonical exit: 20 May 2025 (T+90)
1,476,626 shares@ US$0.504316.4% of flowCommon StockSEC:0001493152-24-039081:0
Canonical exit: 25 Dec 2024 (T+90)
1,476,626 shares@ US$0.50436.6% of flowCommon StockSEC:0001493152-24-039088:0
Canonical exit: 25 Dec 2024 (T+90)
50,000 shares@ US$0.36680.4% of flowCommon StockSEC:0001493152-24-032928:0
Canonical exit: 13 Nov 2024 (T+90)
100,000 shares@ US$0.39680.4% of flowCommon StockSEC:0001493152-24-032673:0
Canonical exit: 12 Nov 2024 (T+90)
39,266 shares@ US$0.396452.3% of flowCommon StockSEC:0001493152-24-032675:0
Canonical exit: 12 Nov 2024 (T+90)
100,000 shares@ US$0.38640.9% of flowCommon StockSEC:0001493152-24-032674:0
Canonical exit: 12 Nov 2024 (T+90)
602,410 shares@ US$1.669.1% of flowCommon StockSEC:0001493152-24-010734:0
78,314 shares@ US$1.662.9% of flowCommon StockSEC:0001493152-24-010735:0
12,048 shares@ US$1.66100.0% of flowCommon StockSEC:0001493152-24-010733:0
11,267 shares@ US$2.06211.4% of flowCommon StockSEC:0001493152-23-046584:0
3,423 shares@ US$2.214100.0% of flowCommon StockSEC:0001493152-23-046580:0
77,775 shares@ US$1.63032.9% of flowCommon StockSEC:0001493152-23-045451:0
Canonical exit: 17 Mar 2024 (T+90)
1,200,000 shares@ US$1.63517.7% of flowCommon StockSEC:0001493152-23-045447:0
Canonical exit: 17 Mar 2024 (T+90)
10,000 shares@ US$1.7715.1% of flowCommon StockSEC:0001493152-23-041880:0
Canonical exit: 14 Feb 2024 (T+90)
250,000 shares@ US$2.6956.1% of flowCommon StockSEC:0001493152-23-030532:0
Canonical exit: 26 Nov 2023 (T+90)
13,614 shares@ US$2.63990.3% of flowCommon StockSEC:0001493152-23-029825:0
Canonical exit: 16 Nov 2023 (T+90)
75,050 shares@ US$2.76421.9% of flowCommon StockSEC:0001493152-23-029825:1
Canonical exit: 19 Nov 2023 (T+90)
5,000 shares@ US$4.5119.3% of flowCommon StockSEC:0001493152-23-023429:0
Canonical exit: 28 Sept 2023 (T+90)
5,000 shares@ US$6.6750.1% of flowCommon StockSEC:0001493152-23-010620:0
Canonical exit: 29 Jun 2023 (T+90)
240,000 shares0Common StockSEC:0001493152-23-010622:0
25 of 70 declarations
关于 Beyond Air, Inc.
Beyond Air, Inc. (NASDAQ: XAIR) 是一家总部位于美国纽约州花园城的美国医疗设备和生物制药公司。该公司最初名为 AIT Therapeutics，并于 2019 年更名为 Beyond Air，同时明确了其围绕治疗性一氧化氮 (NO) 的战略。对于投资者而言，该公司处于医疗保健领域的一个专业细分市场：呼吸护理、医院设备和基于一氧化氮的输送技术。其规模仍然相对较小，但正试图围绕一个具有临床相关性的平台建立差异化的商业足迹。([sec.gov](https://www.sec.gov/Archives/edgar/data/1641631/000164117225015750/form10-k.htm?utm_source=openai)) Beyond Air 的核心平台是 LungFit，它使用其专有的 Ionizer™ 技术从环境空气中生成一氧化氮，而不是依赖传统的钢瓶或其他笨重的供应系统。这种设计是投资案例的核心：该公司将 LungFit 定位为一种更简单、更灵活、可能更清洁的在医院环境中输送吸入式 NO 的方式。其旗舰商业产品是 LungFit PH，而其他变体如 LungFit PRO 和 LungFit GO 则被该公司描述为研究性设备。Beyond Air 还围绕一氧化氮应用进行更广泛的研发工作，一些相关的业务线已随着时间的推移进行重组或转移到附属结构中。([beyondair.net](https://www.beyondair.net/?utm_source=openai)) 在竞争方面，Beyond Air 正寻求挑战传统的一氧化氮输送方法，并通过提供按需、由室内空气生成解决方案来与其它呼吸技术供应商竞争。该公司的信息直截了当：降低物流复杂性，提高医院运营便利性，并支持更具可扩展性的一氧化氮治疗方法。尽管如此，该业务仍处于商业化的早期阶段，面临着医疗技术领域常见的执行风险，包括医院采用率、报销动态、监管里程碑、制造准备情况以及持续的资本需求。实际上，股权故事仍取决于证明该技术能够从临床前景转化为可重复的商业吸引力。([beyondair.net](https://www.beyondair.net/?utm_source=openai)) 最近的发展表明，该公司正从开发阶段迈向更广泛的商业化。2025 年，Beyond Air 报告了显著的收入增长，获得了 LungFit PH 在欧洲的 CE 标志，获得了澳大利亚的市场授权，并表示国际分销协议现已覆盖 30 多个国家和超过 2 billion 人口。管理层还强调了与 Premier, Inc. 签订的集团采购协议，并上调了其 2026 财年收入指引。总而言之，这些更新表明商业推广正在加速，尽管收入仍然适中，且该公司仍处于平台规模化的早期阶段。([sec.gov](https://www.sec.gov/Archives/edgar/data/1641631/000149315225006892/ex99-1.htm?utm_source=openai))
